Human lymphocyte medium adjuvant
US7745157B2 · kind B2 · utility
0Cited by
10References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 20, 2004 |
| Grant date | Jun 29, 2010 |
| Priority date | — |
| Expiry date | Mar 19, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55588
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.